# Tesamorelin for Weight Loss? Read Its Own Label By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-16 | Updated: 2026-10-30 Canonical page: https://glpwatchdog.org/research/tesamorelin-for-weight-loss > Tesamorelin is FDA-approved, for reducing abdominal fat in HIV-associated lipodystrophy. Its label carries six words that matter: “Not indicated for weight loss management.” ## Key points - Approved as EGRIFTA, and only for the abdominal fat that accumulates in HIV-associated lipodystrophy. - The label’s Limitations of Use say plainly: “Not indicated for weight loss management.” - Second limitation: long-term cardiovascular safety has not been established, even in the approved population. - Unlike BPC-157, this IS a real approved drug with two current labels. The objection is the indication, not the existence. Tesamorelin is a real, FDA-approved drug. It is sold as EGRIFTA, made by Theratechnologies, and has a current label you can read today. Its approval covers exactly one job: cutting the visceral fat that builds up in people living with HIV who have developed lipodystrophy. And its label carries a limitation stated in six words: **“Not indicated for weight loss management.”**[1] It is nonetheless marketed for weight loss, frequently alongside GLP-1s, by sellers who lean on the fact that it is approved. The trick is that *approved* and *approved for this* are different claims, and the gap between them is where the marketing lives. Which peptides are approved, and for what, is listed in [FDA-approved peptides](https://glpwatchdog.org/research/fda-approved-peptides). ## What the label actually says Section 1 of the prescribing information describes tesamorelin as a growth hormone-releasing factor analog, and ties its approval to one use: shrinking the surplus fat carried around the abdomen by adults with HIV who have lipodystrophy. Directly beneath that, the label sets out two limitations on what it may be said to do. > “Long-term cardiovascular safety of EGRIFTA WR has not been established.” > > “Not indicated for weight loss management.”[1] > > — FDA label, EGRIFTA WR (tesamorelin) — Limitations of Use HIV-associated lipodystrophy is a specific condition, distinct from the [inherited forms in which fat tissue is missing](https://glpwatchdog.org/research/a-weight-drug-for-having-too-little-fat): a redistribution of body fat seen in some people on long-term antiretroviral therapy, in which visceral fat accumulates around the abdominal organs and sometimes at the back of the neck (a [buffalo hump](https://glpwatchdog.org/research/buffalo-hump-and-weight-loss), which the label does not cover). Tesamorelin was developed for that, tested in that population, and approved for that. As a growth hormone-releasing factor analog, it nudges the pituitary into putting out more of the growth hormone you already make, an entirely different mechanism from a GLP-1. > **The two limitations do different work and both matter.** “Not indicated for weight loss management” tells you the drug was not approved for the purpose it is being sold to you for. “Long-term cardiovascular safety has not been established” tells you that the open question about it has not been answered even in the population it *was* approved for, and those patients are under regular medical supervision, which a peptide buyer is not. ## This is not the BPC-157 situation The peptide market is often discussed as though it were one undifferentiated thing, so it helps to be precise. There are two current FDA labels for tesamorelin, EGRIFTA WR and EGRIFTA SV. It has a manufacturer, an approval, published trials and a prescribing information document. [BPC-157](https://glpwatchdog.org/research/bpc-157-what-fda-actually-said) has none of those. Sermorelin, the older GHRH analog that clinics compound, had an approval that was discontinued; the two are compared in [sermorelin vs tesamorelin](https://glpwatchdog.org/research/sermorelin-vs-tesamorelin). So the objection here is narrower and sharper. Nobody has to argue that tesamorelin is unstudied or unreal. The argument is only that it was studied for a different problem in a different population, and that the label says so on its face. ## Off-label is legal, and this is not quite that A clinician may lawfully prescribe an approved drug outside its labeled indication. Off-label prescribing is legal, common and often good medicine; Ozempic for weight loss is the obvious example in this market. A seller *marketing* a drug for an unapproved use is a different matter. The prescriber's judgment is protected; promotional claims are regulated. When a peptide site advertises tesamorelin for fat loss in the general population, it is making the claim the label specifically excludes, and it is making it to you rather than to a clinician exercising judgment about your case. - **Ask what indication it is being prescribed for.** If you do not have HIV-associated lipodystrophy, ask directly what the clinical reasoning is. - **Ask where it is coming from.** Approved EGRIFTA is dispensed by a pharmacy against a prescription. A vial from a peptide shop labeled “tesamorelin” is not that product, whatever the name on it. - **Ask about cardiovascular monitoring**, given the label's own limitation on long-term cardiovascular safety. - **Ask what evidence supports the use you are being sold.** Trials in HIV-associated lipodystrophy are evidence about HIV-associated lipodystrophy. In practice, tesamorelin now shows up on GLP-1 sellers’ menus, so these are questions for an ordinary telehealth checkout. [Vyora Wellness](https://glpwatchdog.org/reviews/vyora-wellness), [Longevixx](https://glpwatchdog.org/reviews/longevixx) and [Metabolyz](https://glpwatchdog.org/reviews/metabolyz) list it next to compounded semaglutide and tirzepatide. On the second question, [Trellis Vitality](https://glpwatchdog.org/reviews/trellis-vitality) names VialsRx as the pharmacy that fills its prescriptions, while [Believe Health](https://glpwatchdog.org/reviews/believe-health) and [Mirabel Meds](https://glpwatchdog.org/reviews/mirabel-meds) do not name the pharmacies behind their catalogs. Two physician-led clinics also list it, and both give you a prescriber to put the first question to. [Dr. Gillis’ Wellness Center](https://glpwatchdog.org/reviews/dr-gillis-wellness-center) in Maine offers free walk-in consultations, and [Nuform Health](https://glpwatchdog.org/reviews/nuform-health) is a physician-owned clinic in Michigan that sells its medications as prepaid multi-month kits. ## How it compares to what is actually approved for weight If the goal is weight loss, the drugs approved for it have been tested for it at scale. Semaglutide reported 14.9% at 68 weeks in a trial of 1,961 people;[3] tirzepatide 20.9% at 72 weeks in 2,539.[2] Those trials measured weight in people seeking weight loss, which is the question being asked. How the other peptides sold for weight compare on human evidence is in [peptides for weight loss](https://glpwatchdog.org/research/peptides-for-weight-loss). Tesamorelin's trials measured visceral fat in people with HIV-associated lipodystrophy. That is a real and useful finding for those patients, but it does not answer the weight-loss question. Semaglutide has since been tested against that same abdominal fat, in [a placebo-controlled trial in people with HIV](https://glpwatchdog.org/research/glp1-and-hiv-lipohypertrophy). Our [register](https://glpwatchdog.org/reviews) covers the sellers of the drugs that were approved for this, and [what they cost](https://glpwatchdog.org/research/cheapest-glp1-without-insurance). ## Common questions ## Frequently asked questions ### Is tesamorelin FDA-approved? Yes, as EGRIFTA, and the approval is confined to abdominal fat accumulation in people with HIV-associated lipodystrophy. Two current labels exist, EGRIFTA WR and EGRIFTA SV, from Theratechnologies. It is a real approved drug, which is why the limitation on its label carries weight. ### Is tesamorelin approved for weight loss? No, and the label says so in as many words: “Not indicated for weight loss management.” That is printed under Limitations of Use in the prescribing information, and it is free to check. ### Does tesamorelin work for general fat loss? The trials that support its approval measured visceral fat in people with HIV-associated lipodystrophy, a specific condition with specific physiology. Extending that to a general weight-loss population is an assumption, not a finding, and it is the assumption the label declines to make. ### Is tesamorelin safe? It has an approved safety profile for its indication, which is more than most peptides sold online can say. Its label adds a limitation, though: long-term cardiovascular safety has not been established, even in the approved population under medical supervision. ### How is it different from a GLP-1? It works by a completely different mechanism. Tesamorelin is a growth hormone-releasing factor analog, working upstream on the pituitary to raise your own growth hormone output. GLP-1 drugs act on incretin receptors to suppress appetite and slow gastric emptying. They are not alternatives to each other in any meaningful sense. ### Is buying tesamorelin from a peptide site the same drug? No. EGRIFTA is a specific manufactured product dispensed against a prescription. A vial from a research-peptide seller shares a molecule name and nothing else. There is no manufacturer accountability, no pharmacy, and no verification that the contents match the label. ## References 1. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection — prescribing information, Section 1 Indications and Usage and Limitations of Use. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/ 3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ --- Cite as: GLP Watchdog, Ruth Calder, "Tesamorelin for Weight Loss? Read Its Own Label", published 2026-08-16, updated 2026-10-30. https://glpwatchdog.org/research/tesamorelin-for-weight-loss Canonical HTML page: https://glpwatchdog.org/research/tesamorelin-for-weight-loss Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.